The major guidelines for lipid-lowering therapy (LLT) have been revised recently. Although "higher cardiovascular risk-aggressive LLT with greater absolute clinical benefit" is the main idea underlying all guidelines, there are some differences in the details among them. The US guidelines recommend pharmacological LLT based on a patient's risk category, independently of their low-density lipoprotein-cholesterol (LDL-C) level. However, the European and Korean guidelines consider the patient's risk category and LDL-C at the same time. Lifestyle modifications are suggested in parallel in all guidelines. The newest US guidelines have characteristically revived target LDL-C values in some patient groups and indications for non-statin drugs (ezetimibe and PCSK9 inhibitors), whereas the European and Korean guidelines have maintained target LDL-C values as usual. It is universally accepted that statins are the first-line agent. Adding ezetimibe, bile acid sequestrants, or PCSK9 inhibitors is recommended as a second line treatment. Appreciating the trend and background of the newest LLT guidelines will be essential to maximize cardiovascular prevention in patients. (Korean J Med 2019;94:396-402) 
Patient groups, such as ASCVD, DM, severe hypercholesterolemia, or PCE ≥ 7.5% were classified to always take LLT; very high risk ASCVD is defined by several conditions. The need for stratified lipid-lowering therapy is based on the relationship between higher cardiovascular risk, aggressive lipid-lowering therapy, and greater absolute clinical benefit. In this figure, the more centrally located patient group has a higher cardiovascular risk and obtains more clinical benefit from lipid-lowering therapy. DM, diabetes mellitus. 
